Exagen Inc. (XGN)
Stock Price:
$14.70 USD
0.05 (0.34%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
185.81M |
| Revenue (ttm) |
39.19M |
| Net Income (ttm) |
-15.48M |
| Shares Out |
12.64M |
| EPS (ttm) |
-72.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$14.70 |
| Previous Close |
$14.65 |
| Change ($) |
0.05 |
| Change (%) |
0.34% |
| Day's Open |
14.77 |
| Day's Range |
14.59 - 15.25 |
| Day's Volume |
3,716 |
| 52-Week Range |
10.29 - 29.86 |
More Stats
| Market Cap |
185.81M |
| Enterprise Value |
148.36M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.64M |
| Float |
4.94M |
| EPS (basic) |
28.24 |
| EPS (diluted) |
-72.27 |
| FCF / Share |
-1.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
140,768 |
| Short Ratio |
5.14 |
| Short % of Float |
2.85% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.74 |
| PB Ratio |
3.81 |
| Revenue |
39.19M |
| Operating Income |
-13.65M |
| Net Income |
-15.48M |
| Free Cash Flow |
-13.92M |
| Net Cash |
37.45M |
| Net Cash / Share |
2.96 |
| Gross Margin |
55.07% |
| Operating Margin |
-34.84% |
| Profit Margin |
-75.10% |
| FCF Margin |
-35.51% |
| ROA |
-14.80% |
| ROE |
-64.25% |
| ROIC |
-42.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$18.33*
(24.69% upside)
Low
17.0
Current: $14.70
High
20.0
Target: 18.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 40.39 | 32.44 | 26.81 |
| Revenue Growth | 24.5% | 21.01% | - |
| Gross Profit | 21.58 | 17.06 | 12.67 |
| Operating Income | -9.30 | -4.88 | -7.89 |
| Net Income | -12.04 | -8.01 | -25.63 |
| Shares Outstanding | 3.58 | 0.06 | 0.06 |
| Earnings Per Share | -8.46 | -293.34 | -520.18 |
| Operating Cash Flow | -9.71 | -9.30 | -10.97 |
| Capital Expenditures | -0.10 | -0.20 | -0.51 |
| Free Cash Flow | -9.81 | -9.50 | -11.48 |
| Cash & Equivalents | 72.08 | 13.16 | 11.24 |
| Total Debt | 25.85 | 24.62 | 18.81 |
| Net Cash / Debt | 46.23 | -11.45 | -7.57 |
| Assets | 88.31 | 28.89 | 20.39 |
| Liabilities | 32.65 | 35.62 | 25.03 |
| Book Value | 55.66 | -112 | -96.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Exagen Inc. |
| Country |
United States |
| Employees |
153 |
| CEO |
Fortunato Ron Rocca |
Stock Information
| Ticker Symbol |
XGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: XGN |
| IPO Date |
September 19, 2019 |
Description
Exagen develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.